Press Release: Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
01 Febbraio 2024 - 7:30AM
Press Release: Sanofi Delivers Solid Sales and Business EPS Growth
at CER Amidst Successful Product Launches and Advancements in
Immunology Pipeline
Sanofi Delivers Solid Sales and Business EPS Growth at CER
Amidst Successful Product Launches and Advancements in Immunology
Pipeline
Paris, February 1, 2024
Q4 2023 sales growth of 9.3% at CER and business
EPS(1) increase of 8.2% at
CER
- Specialty Care grew 13.7% driven by
Dupixent and ALTUVIIIO launch performance, more than offsetting
competition from generics of Aubagio in all key markets
- Vaccines sales increased strongly
(up 21.1%) mainly as a result of the unprecedented uptake of
Beyfortus, reaching €410 million in the second quarter of its
launch
- General Medicines decline moderated
(down 2.4%), reflecting accelerated growth of core assets (up
6.3%), offset by lower sales of Lantus and non-core asset
divestment
- CHC rose 8.5% due to Digestive
Wellness and Physical and Mental Wellness which benefited from
Qunol acquisition
Full-year 2023 delivered 5.3% sales growth and 5.4%
business EPS growth at CER
- Sales reached €43,070 million
driven by Dupixent (€10,715 million, +34.0%, adding €2.8bn at CER),
Vaccines (up 8.3%) which benefited from strong launch performance
of Beyfortus (€547 millions) and CHC (+6.3%)
- Business EPS(1) of €8.11 down 1.8%
on a reported basis and up 5.4% at CER
- IFRS EPS of €4.31 (down 35.6%)
mainly reflecting an impairment loss of technology assets resulting
from de-prioritization of R&D programs and a charge related to
the liability remeasurement of expected future royalty payments on
U.S. Beyfortus sales, which mainly occurred in Q4
- Board held on January 31, proposes
annual dividend of €3.76 an increase of 5.6%
R&D transformation and Key
milestones in Q4
- Strong pipeline including record 12
blockbuster opportunities under clinical evaluation detailed at
recent R&D Day
- Dupixent submitted for COPD
(Chronic Obstructive Pulmonary Disease) in the U.S., EU, and
China
- Sarclisa delivered positive phase 3
results in 1L transplant-ineligible Multiple Myeloma (IMROZ)
Progress on Corporate Social
Responsibility strategy in Q4
- Sanofi Global Health Unit announced
three new investments through its Impact Fund to support healthcare
start-ups in Sub-Saharan Africa
- Sanofi at COP28: supporting the
decarbonization of healthcare systems
Full-year 2024 business EPS
guidance
- Sanofi expects
2024 business EPS(1) to remain roughly stable excluding the impact
of an expected effective tax rate increase to 21% and decrease low
single-digit(2) at CER including the higher expected tax rate,
barring unforeseen major adverse events. Applying average January
2024 exchange rates, the currency impact on 2024 business EPS is
estimated between -3.5% to -4.5%.
Paul Hudson, Sanofi Chief Executive Officer,
commented:
“2023 marked a critical year on our journey to
become a development-driven, tech-powered biopharma company
committed to serving patients and accelerating growth. We have
delivered another year of strong underlying performance of our core
drivers in Specialty Care and Vaccines supported by the outstanding
launch execution of Beyfortus, Altuviiio and Tzield. With
scientific news flow at an all-time high, pipeline advances and 12
potential blockbusters in late-stage development including
amlitelimab, frexalimab and tolebrutinib, our R&D
transformation has reached an inflection point on the road to
industry leadership in immunology. Looking forward, we remain
committed to investing in R&D to fully unlock the value of our
pipeline, powered by AI at scale, and continue to focus on our
expected launch opportunities such as Dupixent in COPD. At the same
time, we are taking steps to become a pure-play biopharma company
with more than €10bn sales contribution from Pharma launches by
2030(4).”
|
Q4 2023 |
Change |
Change at CER |
2023 |
Change |
Change at CER |
IFRS net sales
reported |
€10,919m |
+1.8% |
+9.3% |
€43,070m |
+0.2% |
+5.3% |
IFRS net income
reported |
-€555m |
-117.8% |
_ |
€5,400m |
-35.5% |
— |
IFRS EPS reported |
-€0.44 |
-117.7% |
_ |
€4.31 |
-35.6% |
— |
Free cash flow(3) |
€3,496m |
+37.3% |
_ |
€8,478m |
-0.1% |
— |
Business
operating income |
€2,583m |
-5.2% |
+5.3% |
€12,670m |
-2.8% |
+4.3% |
Business net
income(1) |
€2,083m |
-2.7% |
+8.2% |
€10,155m |
-1.8% |
+5.5% |
Business EPS(1) |
€1.66 |
-2.9% |
+8.2% |
€8.11 |
-1.8% |
+5.4% |
Changes in net sales are expressed at constant
exchange rates (CER) unless otherwise indicated (definition in
Appendix 9). (1) In order to facilitate an understanding of
operational performance, Sanofi comments on the business net income
statement. Business net income is a non-IFRS financial measure
(definition in Appendix 9). The consolidated income statement for
Q4 2023 is provided in Appendix 3 and a reconciliation of reported
IFRS net income to business net income is set forth in Appendix 4;
(2) 2023 business EPS was €8.11; (3) Free cash flow is a non-IFRS
financial measure (definition in Appendix 9). (4) Risk-adjusted net
sales at CER . Already launched: ALTUVIIIO, TZIELD, Sarclisa,
Nexviazyme, Rezurock, Xenpozyme, Enjaymo, Cablivi; Potential
launches tolebrutinib, itepekimab, amlitelimab, frexalimab,
rilzabrutinib, lunsekimig, Oral TNFR1si
Grafico Azioni Sanofi (BIT:1SAN)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Sanofi (BIT:1SAN)
Storico
Da Giu 2023 a Giu 2024